WM Healthcare Solutions Signals Back-Half Volume Revival and Pricing Strength in Q2 2026

WM Healthcare Solutions: volume, pricing trends, and growth outlook

Volume trend: improving, but characterized as a “back-half” story

• In the quarter, management characterized Healthcare Solutions volume as “a little bit lighter than what we were expecting” ¹.
• They also reiterated that volume improvement was expected to show up more in the back half of the year, and they stated they were “already starting to see that” ².
• On the revenue-quality and demand side, they cited cross-selling improvement in Q2, including cross-selling up to $32 million (with an original synergy target of $50 million) ².
• Looking further, management described Healthcare Solutions as having known headwinds on the hospital side (~$40 million of losses) that were “sunsetting,” and they expected to benefit from moderation of earlier “volume wins” headwinds in the first half into the second half ³.

Interpretation (from the transcript): WM’s Healthcare Solutions volume trajectory appears to be transitioning from earlier integration/operational friction into more normalized demand and Commercial execution, with volume growth expected to be more visible in the second half rather than being fully reflected in the first half results ²³¹.

Pricing trend: ongoing improvement and a stronger exit-rate into year-end

• Management stated they expect “price performance [to] continue to improve” for the revenue quality issues addressed earlier ³.
• They gave explicit pricing performance targets for Healthcare Solutions as an enterprise-level metric: WM HS “exit the year at 5.7%,” with the quarter at “4.5%,” and continued improvement on the cost side ⁴.
• They also indicated that price acceleration through the back half of the year was expected, and that there were confidence-building indicators from earlier quarters’ volume wins moderating in the first half—which should make second-half benefits clearer ³.
• On revenue-quality dynamics, they tied improvement to DSO falling by 5 days (i.e., faster collections), with customer credits that “peaked in Q4,” then declined in Q1 and again in Q2, becoming a tailwind in the back half affecting both top and bottom line ².

Interpretation: The pricing picture is not described as stable—it is portrayed as actively improving, with Healthcare Solutions price increasing from 4.5% in the quarter to 5.7% at year-end, and with additional support from revenue-quality normalization (credits trending down) ⁴²³.

How WM is describing the “volume vs. price” balance and its impact on growth

• Management framed the year as “volume-driven adjustment” on the broader Collection/Disposal side, but they simultaneously emphasized better-than-planned pricing execution and Healthcare Solutions outlook improvement as part of confidence in guidance ⁵.
• In the Healthcare Solutions segment specifically, they described it as a driver of “strong EBITDA pricing” and SG&A performance in Q2 ².
• They also highlighted that cross-selling and cost synergy capture are contributing to improved Healthcare Solutions earnings power, while also noting that cross-selling synergies will accrue beyond just the Healthcare segment ⁶.

Key point: WM’s narrative suggests growth is coming from both (1) better commercial execution (pricing and cross-selling) and (2) operational integration/cost synergy capture, rather than from pure volume expansion alone ²⁶³.

Growth outlook going forward (medium and longer term)

Near-to-medium term (back half of 2026)

• Management’s expectation is that Healthcare Solutions volume is a “back half of the year story” and that they were already seeing early signs of it ².
• They stated confidence that price will accelerate in the back half of the year, and that moderated volume-win benefits from earlier quarters should translate more clearly into the second half ³.
• They also described the Healthcare Solutions platform as “fixed” and integrated, stating management believes it is “turning into exactly what we hoped when we bought it initially” ⁷.

Medium-to-long term

• Management explicitly tied the Healthcare business attractiveness to structural tailwinds: healthcare/aging demographics and growing healthcare expenses, stating “none of those are changing” and expressing sustained optimism for the business over the medium and long term ⁸.
• They further characterized integration as complete enough to shift focus from “short-term items” to the medium and long term business model and sales execution (national accounts, pricing team, operating team) ⁸.

Evidence WM is getting stronger economically (supporting the growth thesis)

While your question focuses on volume/pricing/outlook, the transcript provides relevant confirmation of improving business economics that typically accompany sustainable growth:

• Healthcare Solutions operating EBITDA margin expanded 200 bps to 19% in Q2, while SG&A expense declined 15% and improved 290 bps as a percentage of revenue ⁹.
• Management stated they were seeing integration benefits such as cross-selling up to $32 million and that WM HS is contributing to broader portfolio benefits as it becomes “integrated” ²¹⁰⁶.
• They also noted that Healthcare Solutions cost synergy execution continued (SG&A within WM HS dropping from 24–25% when first acquired to 18% at end of quarter, with an expectation of 15–16% by end of year) ¹¹.

Bottom line answer

• Volume trend: Healthcare Solutions volume was initially lighter than expected, but management expects volume improvement to be more pronounced in the back half of the year, with evidence of improving commercial activity via cross-selling ¹².
• Pricing trend: Pricing is improving, with WM HS price performance expected to exit 2026 at 5.7% after being 4.5% in the quarter, supported by continued improvement in revenue quality (e.g., customer credits peaking then declining) ⁴²³.
• Growth outlook: Near-term growth is framed as back-half strengthening as integration friction moderates and earlier headwinds sunset, while the medium-to-long term outlook remains structurally positive given demographics and rising healthcare spend, with management stating it has not changed its optimism ²³⁷⁸.